Constitutively active chemokine CXC receptors

Advances in Pharmacology

Volumn 70, Issue , 2014, Pages 265-301

  Han, Xinbing ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Biased signaling; Chemokine CXC receptors; Constitutively active mutants; CXC chemokine; Dimerization; G protein signaling; Inflammation; Inverse antagonist; Small molecule design; Tumor

Indexed keywords

ALPHA CHEMOKINE; CHEMOKINE RECEPTOR CXCR; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR3; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR5; CHEMOKINE RECEPTOR CXCR6; CHEMOKINE RECEPTOR CXCR7; G PROTEIN COUPLED RECEPTOR; HETERODIMER; LIGAND; RETINA S ANTIGEN; CHEMOKINE RECEPTOR;

ALLOSTERISM; ARTICLE; AUTOIMMUNE DISEASE; CALCIUM MOBILIZATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; GENE MUTATION; HUMAN; LIGAND BINDING; NEOPLASM; NONHUMAN; PATHOGENESIS; POINT MUTATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN TERTIARY STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; DISEASES; GENETICS; METABOLISM; MUTATION;

ANIMALS; DISEASE; HUMANS; LIGANDS; MUTATION; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84902187996     PISSN: 10543589     EISSN: 15578925     Source Type: Book Series    
DOI: 10.1016/B978-0-12-417197-8.00009-2     Document Type: Chapter

References (148)

1. Abel S., Hundhausen C., Mentlein R., Schulte A., Berkhout T.A., Broadway N., et al. The transmembrane CXC-chemokine ligand 16 is induced by IFN-gamma and TNF-alpha and shed by the activity of the disintegrin-like metalloproteinase ADAM10. Journal of Immunology 2004, 172(10):6362-6372.
2. Acosta J.C., O'Loghlen A., Banito A., Raguz S., Gil J. Control of senescence by CXCR2 and its ligands. Cell Cycle 2008, 7(19):2956-2959.
3. Addison C.L., Daniel T.O., Burdick M.D., Liu H., Ehlert J.E., Xue Y.Y., et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. Journal of Immunology 2000, 165(9):5269-5277.
4. Aiuti A., Webb I.J., Bleul C., Springer T., Gutierrez-Ramos J.C. The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. Journal of Experimental Medicine 1997, 185(1):111-120.
5. Alkhatib G. The biology of CCR5 and CXCR4. Current Opinion in HIV and AIDS 2009, 4(2):96-103.
6. Alvarez Arias D., Navenot J.M., Zhang W.B., Broach J., Peiper S.C. Constitutive activation of CCR5 and CCR2 induced by conformational changes in the conserved TXP motif in transmembrane helix 2. Journal of Biological Chemistry 2003, 278(38):36513-36521.
7. Amine A., Rivera S., Opolon P., Dekkal M., Biard D.S., Bouamar H., et al. Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One 2009, 4(3):e5018.
8. Ansel K.M., Harris R.B., Cyster J.G. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 2002, 16(1):67-76.
9. Ansel K.M., Ngo V.N., Hyman P.L., Luther S.A., Forster R., Sedgwick J.D., et al. A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 2000, 406(6793):309-314.
10. Arvanitakis L., Geras-Raaka E., Varma A., Gershengorn M.C., Cesarman E. Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation. Nature 1997, 385(6614):347-350.
11. Bais C., Van Geelen A., Eroles P., Mutlu A., Chiozzini C., Dias S., et al. Kaposi's sarcoma associated herpesvirus G protein-coupled receptor immortalizes human endothelial cells by activation of the VEGF receptor-2/KDR. Cancer Cell 2003, 3(2):131-143.
12. Bakker R.A., Jongejan A., Sansuk K., Hacksell U., Timmerman H., Brann M.R., et al. Constitutively active mutants of the histamine H1 receptor suggest a conserved hydrophobic asparagine-cage that constrains the activation of class A G protein-coupled receptors. Molecular Pharmacology 2008, 73(1):94-103.
13. Balabanian K., Lagane B., Infantino S., Chow K.Y., Harriague J., Moepps B., et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. Journal of Biological Chemistry 2005, 280(42):35760-35766.
14. Balkwill F. Cancer and the chemokine network. Nature Reviews Cancer 2004, 4(7):540-550.
15. Berchiche Y.A., Chow K.Y., Lagane B., Leduc M., Percherancier Y., Fujii N., et al. Direct assessment of CXCR4 mutant conformations reveals complex link between receptor structure and G(alpha)(i) activation. Journal of Biological Chemistry 2007, 282(8):5111-5115.
16. Bizzarri C., Beccari A.R., Bertini R., Cavicchia M.R., Giorgini S., Allegretti M. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets. Pharmacology &Therapeutics 2006, 112(1):139-149.
17. Bleul C.C., Farzan M., Choe H., Parolin C., Clark-Lewis I., Sodroski J., et al. The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 1996, 382(6594):829-833.
18. Boldajipour B., Mahabaleshwar H., Kardash E., Reichman-Fried M., Blaser H., Minina S., et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 2008, 132(3):463-473.
19. Burger M., Burger J.A., Hoch R.C., Oades Z., Takamori H., Schraufstatter I.U. Point mutation causing constitutive signaling of CXCR2 leads to transforming activity similar to Kaposi's sarcoma herpesvirus-G protein-coupled receptor. Journal of Immunology 1999, 163(4):2017-2022.
20. Burger M., Hartmann T., Burger J.A., Schraufstatter I. KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene 2005, 24(12):2067-2075.
21. Burns J.M., Summers B.C., Wang Y., Melikian A., Berahovich R., Miao Z., et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. Journal of Experimental Medicine 2006, 203(9):2201-2213.
22. Canals M., Scholten D.J., de Munnik S., Han M.K., Smit M.J., Leurs R. Ubiquitination of CXCR7 controls receptor trafficking. PLoS One 2012, 7(3):e34192.
23. Cannon M., Philpott N.J., Cesarman E. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor has broad signaling effects in primary effusion lymphoma cells. Journal of Virology 2003, 77(1):57-67.
24. Cesarman E. The role of Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases. Recent Results in Cancer Research 2002, 159:27-37.
25. Chapman R.W., Phillips J.E., Hipkin R.W., Curran A.K., Lundell D., Fine J.S. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacology & Therapeutics 2009, 121(1):55-68.
26. Cheng Z.J., Zhao J., Sun Y., Hu W., Wu Y.L., Cen B., et al. Beta-arrestin differentially regulates the chemokine receptor CXCR4-mediated signaling and receptor internalization, and this implicates multiple interaction sites between beta-arrestin and CXCR4. Journal of Biological Chemistry 2000, 275(4):2479-2485.
27. Colvin R.A., Campanella G.S., Sun J., Luster A.D. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. Journal of Biological Chemistry 2004, 279(29):30219-30227.
28. Couty J.P., Geras-Raaka E., Weksler B.B., Gershengorn M.C. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor signals through multiple pathways in endothelial cells. Journal of Biological Chemistry 2001, 276(36):33805-33811.
29. Couty J.P., Gershengorn M.C. Insights into the viral G protein-coupled receptor encoded by human herpesvirus type 8 (HHV-8). Biology of the Cell 2004, 96(5):349-354.
30. Cyster J.G., Ansel K.M., Reif K., Ekland E.H., Hyman P.L., Tang H.L., et al. Follicular stromal cells and lymphocyte homing to follicles. Immunological Reviews 2000, 176:181-193.
31. Decaillot F.M., Kazmi M.A., Lin Y., Ray-Saha S., Sakmar T.P., Sachdev P. CXCR7/CXCR4 heterodimer constitutively recruits beta-arrestin to enhance cell migration. Journal of Biological Chemistry 2011, 286(37):32188-32197.
32. Feniger-Barish R., Ran M., Zaslaver A., Ben-Baruch A. Differential modes of regulation of cxc chemokine-induced internalization and recycling of human CXCR1 and CXCR2. Cytokine 1999, 11(12):996-1009.
33. Finch D.K., Ettinger R., Karnell J.L., Herbst R., Sleeman M.A. Effects of CXCL13 inhibition on lymphoid follicles in models of autoimmune disease. European Journal of Clinical Investigation 2013, 43(5):501-509.
34. Forster R., Mattis A.E., Kremmer E., Wolf E., Brem G., Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 1996, 87(6):1037-1047.
35. Fredriksson R., Schioth H.B. The repertoire of G-protein-coupled receptors in fully sequenced genomes. Molecular Pharmacology 2005, 67(5):1414-1425.
36. Ganju R.K., Brubaker S.A., Meyer J., Dutt P., Yang Y., Qin S., et al. The alpha-chemokine, stromal cell-derived factor-1alpha, binds to the transmembrane G-protein-coupled CXCR-4 receptor and activates multiple signal transduction pathways. Journal of Biological Chemistry 1998, 273(36):23169-23175.
37. Gao Q., Zhao Y.J., Wang X.Y., Qiu S.J., Shi Y.H., Sun J., et al. CXCR6 upregulation contributes to a proinflammatory tumor microenvironment that drives metastasis and poor patient outcomes in hepatocellular carcinoma. Cancer Research 2012, 72(14):3546-3556.
38. Geras-Raaka E., Varma A., Ho H., Clark-Lewis I., Gershengorn M.C. Human interferon-gamma-inducible protein 10 (IP-10) inhibits constitutive signaling of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Journal of Experimental Medicine 1998, 188(2):405-408.
39. Germanov E., Veinotte L., Cullen R., Chamberlain E., Butcher E.C., Johnston B. Critical role for the chemokine receptor CXCR6 in homeostasis and activation of CD1d-restricted NKT cells. Journal of Immunology 2008, 181(1):81-91.
40. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. Journal of Clinical Investigation 2010, 120(2):485-497.
41. Gosling J., Monteclaro F.S., Atchison R.E., Arai H., Tsou C.L., Goldsmith M.A., et al. Molecular uncoupling of C-C chemokine receptor 5-induced chemotaxis and signal transduction from HIV-1 coreceptor activity. Proceedings of the National Academy of Science 1997, 94(10):5061-5066.
42. Gough P.J., Garton K.J., Wille P.T., Rychlewski M., Dempsey P.J., Raines E.W. A disintegrin and metalloproteinase 10-mediated cleavage and shedding regulates the cell surface expression of CXC chemokine ligand 16. Journal of Immunology 2004, 172(6):3678-3685.
43. Gunther C., Carballido-Perrig N., Kaesler S., Carballido J.M., Biedermann T. CXCL16 and CXCR6 are upregulated in psoriasis and mediate cutaneous recruitment of human CD8+ T cells. The Journal of Investigative Dermatology 2012, 132(3 Pt 1):626-634.
44. Han M., Smith S.O., Sakmar T.P. Constitutive activation of opsin by mutation of methionine 257 on transmembrane helix 6. Biochemistry 1998, 37(22):8253-8261.
45. Han X., Tachado S.D., Koziel H., Boisvert W.A. Leu128(3.43) (l128) and Val247(6.40) (V247) of CXCR1 are critical amino acid residues for g protein coupling and receptor activation. PLoS One 2012, 8:e42765.
46. Hartmann T.N., Grabovsky V., Pasvolsky R., Shulman Z., Buss E.C., Spiegel A., et al. A crosstalk between intracellular CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation but not in chemokine-triggered motility of human T lymphocytes and CD34+ cells. Journal of Leukocyte Biology 2008, 84(4):1130-1140.
47. Hensbergen P.J., Wijnands P.G., Schreurs M.W., Scheper R.J., Willemze R., Tensen C.P. The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis. Journal of Immunotherapy 2005, 28(4):343-351.
48. Hertzer K.M., Donald G.W., Hines O.J. CXCR2: A target for pancreatic cancer treatment?. Expert Opinion on Therapeutic Targets 2013, 17(6):667-680.
49. Ho H.H., Du D., Gershengorn M.C. The N terminus of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor is necessary for high affinity chemokine binding but not for constitutive activity. Journal of Biological Chemistry 1999, 274(44):31327-31332.
50. Ho H.H., Ganeshalingam N., Rosenhouse-Dantsker A., Osman R., Gershengorn M.C. Charged residues at the intracellular boundary of transmembrane helices 2 and 3 independently affect constitutive activity of Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Journal of Biological Chemistry 2001, 276(2):1376-1382.
51. Holst P.J., Rosenkilde M.M., Manfra D., Chen S.C., Wiekowski M.T., Holst B., et al. Tumorigenesis induced by the HHV8-encoded chemokine receptor requires ligand modulation of high constitutive activity. Journal of Clinical Investigation 2001, 108(12):1789-1796.
52. Infantino S., Moepps B., Thelen M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. Journal of Immunology 2006, 176(4):2197-2207.
53. Jahnichen S., Blanchetot C., Maussang D., Gonzalez-Pajuelo M., Chow K.Y., Bosch L., et al. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proceedings of the National Academy of Science 2010, 107(47):20565-20570.
54. Jamieson T., Clarke M., Steele C.W., Samuel M.S., Neumann J., Jung A., et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. Journal of Clinical Investigation 2012, 122(9):3127-3144.
55. Joseph P.R., Sarmiento J.M., Mishra A.K., Das S.T., Garofalo R.P., Navarro J., et al. Probing the role of CXC motif in chemokine CXCL8 for high affinity binding and activation of CXCR1 and CXCR2 receptors. Journal of Biological Chemistry 2010, 285(38):29262-29269.
56. Kalatskaya I., Berchiche Y.A., Gravel S., Limberg B.J., Rosenbaum J.S., Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Molecular Pharmacology 2009, 75(5):1240-1247.
57. Koch A.E., Polverini P.J., Kunkel S.L., Harlow L.A., DiPietro L.A., Elner V.M., et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992, 258(5089):1798-1801.
58. Korniejewska A., McKnight A.J., Johnson Z., Watson M.L., Ward S.G. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology 2011, 132(4):503-515.
59. La Porta C.A. CXCR6: The role of environment in tumor progression. Challenges for therapy. Stem Cell Reviews and Reports 2012, 8(4):1282-1285.
60. Lagane B., Ballet S., Planchenault T., Balabanian K., Le Poul E., Blanpain C., et al. Mutation of the DRY motif reveals different structural requirements for the CC chemokine receptor 5-mediated signaling and receptor endocytosis. Molecular Pharmacology 2005, 67(6):1966-1976.
61. Levoye A., Balabanian K., Baleux F., Bachelerie F., Lagane B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 2009, 113(24):6085-6093.
62. Luker K.E., Gupta M., Luker G.D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB Journal 2009, 23(3):823-834.
63. Luster A.D., Leder P. IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo. Journal of Experimental Medicine 1993, 178(3):1057-1065.
64. Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment. Immunity 1999, 10(4):463-471.
65. Malik R., Marchese A. Arrestin-2 interacts with the endosomal sorting complex required for transport machinery to modulate endosomal sorting of CXCR4. Molecular Biology of the Cell 2010, 21(14):2529-2541.
66. Marchese A., Raiborg C., Santini F., Keen J.H., Stenmark H., Benovic J.L. The E3 ubiquitin ligase AIP4 mediates ubiquitination and sorting of the G protein-coupled receptor CXCR4. Developmental Cell 2003, 5(5):709-722.
67. Matloubian M., David A., Engel S., Ryan J.E., Cyster J.G. A transmembrane CXC chemokine is a ligand for HIV-coreceptor Bonzo. Nature Immunology 2000, 1(4):298-304.
68. Mazzinghi B., Ronconi E., Lazzeri E., Sagrinati C., Ballerini L., Angelotti M.L., et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. Journal of Experimental Medicine 2008, 205(2):479-490.
69. Meijer J., Ogink J., Roos E. Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo. British Journal of Cancer 2008, 99(9):1493-1501.
70. Mesri E.A., Cesarman E., Boshoff C. Kaposi's sarcoma and its associated herpesvirus. Nature Reviews Cancer 2010, 10(10):707-719.
71. Miao Z., Luker K.E., Summers B.C., Berahovich R., Bhojani M.S., Rehemtulla A., et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proceedings of the National Academy of Science 2007, 104(40):15735-15740.
72. Montaner S., Kufareva I., Abagyan R., Gutkind J.S. Molecular mechanisms deployed by virally encoded G protein-coupled receptors in human diseases. Annual Review of Pharmacology and Toxicology 2013, 53:331-354.
73. Montaner S., Sodhi A., Molinolo A., Bugge T.H., Sawai E.T., He Y., et al. Endothelial infection with KSHV genes in vivo reveals that vGPCR initiates Kaposi's sarcomagenesis and can promote the tumorigenic potential of viral latent genes. Cancer Cell 2003, 3(1):23-36.
74. Montaner S., Sodhi A., Pece S., Mesri E.A., Gutkind J.S. The Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor promotes endothelial cell survival through the activation of Akt/protein kinase B. Cancer Research 2001, 61(6):2641-2648.
75. Montaner S., Sodhi A., Servitja J.M., Ramsdell A.K., Barac A., Sawai E.T., et al. The small GTPase Rac1 links the Kaposi sarcoma-associated herpesvirus vGPCR to cytokine secretion and paracrine neoplasia. Blood 2004, 104(9):2903-2911.
76. Muehlinghaus G., Cigliano L., Huehn S., Peddinghaus A., Leyendeckers H., Hauser A.E., et al. Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood 2005, 105(10):3965-3971.
77. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410(6824):50-56.
78. Murphy P.M., Baggiolini M., Charo I.F., Hebert C.A., Horuk R., Matsushima K., et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacological Reviews 2000, 52(1):145-176.
79. Mutlu A.D., Cavallin L.E., Vincent L., Chiozzini C., Eroles P., Duran E.M., et al. In vivo-restricted and reversible malignancy induced by human herpesvirus-8 KSHV: A cell and animal model of virally induced Kaposi's sarcoma. Cancer Cell 2007, 11(3):245-258.
80. Nagasawa T., Hirota S., Tachibana K., Takakura N., Nishikawa S., Kitamura Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 1996, 382(6592):635-638.
81. Nakayama T., Hieshima K., Izawa D., Tatsumi Y., Kanamaru A., Yoshie O. Cutting edge: Profile of chemokine receptor expression on human plasma cells accounts for their efficient recruitment to target tissues. Journal of Immunology 2003, 170(3):1136-1140.
82. Naumann U., Cameroni E., Pruenster M., Mahabaleshwar H., Raz E., Zerwes H.G., et al. CXCR7 functions as a scavenger for CXCL12 and CXCL11. PLoS One 2010, 5(2):e9175.
83. O'Hayre M., Vazquez-Prado J., Kufareva I., Stawiski E.W., Handel T.M., Seshagiri S., et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. Nature Reviews Cancer 2013, 13(6):412-424.
84. Paavola K.J., Hall R.A. Adhesion G protein-coupled receptors: Signaling, pharmacology, and mechanisms of activation. Molecular Pharmacology 2012, 82(5):777-783.
85. Panina P., Mariani M., D'Ambrosio D. Chemokine receptors in chronic obstructive pulmonary disease (COPD). Current Drug Targets 2006, 7(6):669-674.
86. Park S.H., Das B.B., Casagrande F., Tian Y., Nothnagel H.J., Chu M., et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 2012, 491(7426):779-783.
87. Pati S., Cavrois M., Guo H.G., Foulke J.S., Kim J., Feldman R.A., et al. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: Evidence for a paracrine model of Kaposi's sarcoma pathogenesis. Journal of Virology 2001, 75(18):8660-8673.
88. Pati S., Foulke J.S., Barabitskaya O., Kim J., Nair B.C., Hone D., et al. Human herpesvirus 8-encoded vGPCR activates nuclear factor of activated T cells and collaborates with human immunodeficiency virus type 1 Tat. Journal of Virology 2003, 77(10):5759-5773.
89. Peled A., Grabovsky V., Habler L., Sandbank J., Arenzana-Seisdedos F., Petit I., et al. The chemokine SDF-1 stimulates integrin-mediated arrest of CD34(+) cells on vascular endothelium under shear flow. Journal of Clinical Investigation 1999, 104(9):1199-1211.
90. Pierce K.L., Premont R.T., Lefkowitz R.J. Seven-transmembrane receptors. Nature Reviews Molecular Cell Biology 2002, 3(9):639-650.
91. Prado G.N., Suetomi K., Shumate D., Maxwell C., Ravindran A., Rajarathnam K., et al. Chemokine signaling specificity: Essential role for the N-terminal domain of chemokine receptors. Biochemistry 2007, 46(31):8961-8968.
92. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007, 110(1):37-44.
93. Ptasznik A., Urbanowska E., Chinta S., Costa M.A., Katz B.A., Stanislaus M.A., et al. Crosstalk between BCR/ABL oncoprotein and CXCR4 signaling through a Src family kinase in human leukemia cells. Journal of Experimental Medicine 2002, 196(5):667-678.
94. Rabin R.L., Park M.K., Liao F., Swofford R., Stephany D., Farber J.M. Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. Journal of Immunology 1999, 162(7):3840-3850.
95. Rabquer B.J., Tsou P.S., Hou Y., Thirunavukkarasu E., Haines G.K., Impens A.J., et al. Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. Arthritis Research & Therapy 2011, 13(1):R18.
96. Rajagopal S., Kim J., Ahn S., Craig S., Lam C.M., Gerard N.P., et al. Beta-arrestin- but not G protein-mediated signaling by the "decoy" receptor CXCR7. Proceedings of the National Academy of Science 2010, 107(2):628-632.
97. Rajagopalan L., Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. Journal of Biological Chemistry 2004, 279(29):30000-30008.
98. Rasmussen S.G., Choi H.J., Fung J.J., Pardon E., Casarosa P., Chae P.S., et al. Structure of a nanobody-stabilized active state of the beta(2) adrenoceptor. Nature 2011, 469(7329):175-180.
99. Rasmussen S.G., DeVree B.T., Zou Y., Kruse A.C., Chung K.Y., Kobilka T.S., et al. Crystal structure of the beta2 adrenergic receptor-Gs protein complex. Nature 2011, 477(7366):549-555.
100. Ray P., Mihalko L.A., Coggins N.L., Moudgil P., Ehrlich A., Luker K.E., et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. International Journal of Biochemistry & Cell Biology 2012, 44(4):669-678.
101. Rhodes L.V., Short S.P., Neel N.F., Salvo V.A., Zhu Y., Elliott S., et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Research 2011, 71(2):603-613.
102. Richardson R.M., Marjoram R.J., Barak L.S., Snyderman R. Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. Journal of Immunology 2003, 170(6):2904-2911.
103. Roland J., Murphy B.J., Ahr B., Robert-Hebmann V., Delauzun V., Nye K.E., et al. Role of the intracellular domains of CXCR4 in SDF-1-mediated signaling. Blood 2003, 101(2):399-406.
104. Rosenbaum D.M., Rasmussen S.G., Kobilka B.K. The structure and function of G-protein-coupled receptors. Nature 2009, 459(7245):356-363.
105. Rosenbaum D.M., Zhang C., Lyons J.A., Holl R., Aragao D., Arlow D.H., et al. Structure and function of an irreversible agonist-beta(2) adrenoceptor complex. Nature 2011, 469(7329):236-240.
106. Sabroe I., Whyte M.K. Incapacitating the immune system in cystic fibrosis. Nature Medicine 2007, 13(12):1417-1418.
107. Sallusto F., Baggiolini M. Chemokines and leukocyte traffic. Nature Immunology 2008, 9(9):949-952.
108. Sanchez-Martin L., Sanchez-Mateos P., Cabanas C. CXCR7 impact on CXCL12 biology and disease. Trends in Molecular Medicine 2013, 19(1):12-22.
109. Sauty A., Colvin R.A., Wagner L., Rochat S., Spertini F., Luster A.D. CXCR3 internalization following T cell-endothelial cell contact: Preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11). Journal of Immunology 2001, 167(12):7084-7093.
110. Scheerer P., Park J.H., Hildebrand P.W., Kim Y.J., Krauss N., Choe H.W., et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 2008, 455(7212):497-502.
111. Schols D., Struyf S., Van Damme J., Este J.A., Henson G., De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. Journal of Experimental Medicine 1997, 186(8):1383-1388.
112. Schwarz M., Murphy P.M. Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor constitutively activates NF-kappa B and induces proinflammatory cytokine and chemokine production via a C-terminal signaling determinant. Journal of Immunology 2001, 167(1):505-513.
113. Shamaladevi N., Lyn D.A., Escudero D.O., Lokeshwar B.L. CXC receptor-1 silencing inhibits androgen-independent prostate cancer. Cancer Research 2009, 69(21):8265-8274.
114. Sharma B., Singh S., Varney M.L., Singh R.K. Targeting CXCR1/CXCR2 receptor antagonism in malignant melanoma. Expert Opinion on Therapeutic Targets 2010, 14(4):435-442.
115. Smit M.J., Verdijk P., van der Raaij-Helmer E.M., Navis M., Hensbergen P.J., Leurs R., et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK/p44/p42 MAPK nor Akt/PI-3 kinase. Blood 2003, 102(6):1959-1965.
116. Smit M.J., Verzijl D., Casarosa P., Navis M., Timmerman H., Leurs R. Kaposi's sarcoma-associated herpesvirus-encoded G protein-coupled receptor ORF74 constitutively activates p44/p42 MAPK and Akt via G(i) and phospholipase C-dependent signaling pathways. Journal of Virology 2002, 76(4):1744-1752.
117. Snelgrove R.J. Targeting of a common receptor shared by CXCL8 and N-Ac-PGP as a therapeutic strategy to alleviate chronic neutrophilic lung diseases. European Journal of Pharmacology 2011, 667(1-3):1-5.
118. Sodhi A., Chaisuparat R., Hu J., Ramsdell A.K., Manning B.D., Sausville E.A., et al. The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. Cancer Cell 2006, 10(2):133-143.
119. Sodhi A., Montaner S., Patel V., Zohar M., Bais C., Mesri E.A., et al. The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase and p38 pathways acting on hypoxia-inducible factor 1alpha. Cancer Research 2000, 60(17):4873-4880.
120. Spalding T.A., Burstein E.S., Henderson S.C., Ducote K.R., Brann M.R. Identification of a ligand-dependent switch within a muscarinic receptor. Journal of Biological Chemistry 1998, 273(34):21563-21568.
121. Standfuss J., Edwards P.C., D'Antona A., Fransen M., Xie G., Oprian D.D., et al. The structural basis of agonist-induced activation in constitutively active rhodopsin. Nature 2011, 471(7340):656-660.
122. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25(6):977-988.
123. Sun Y., Cheng Z., Ma L., Pei G. Beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation. Journal of Biological Chemistry 2002, 277(51):49212-49219.
124. Tachibana K., Hirota S., Iizasa H., Yoshida H., Kawabata K., Kataoka Y., et al. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature 1998, 393(6685):591-594.
125. Titus B., Schwartz M.A., Theodorescu D. Rho proteins in cell migration and metastasis. Critical Reviews in Eukaryotic Gene Expression 2005, 15(2):103-114.
126. Tsai H.H., Frost E., To V., Robinson S., Ffrench-Constant C., Geertman R., et al. The chemokine receptor CXCR2 controls positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. Cell 2002, 110(3):373-383.
127. Vaidehi N., Bhattacharya S., Larsen A.B. Structure and dynamics of g-protein coupled receptors. Advances in Experimental Medicine & Biology 2014, 796:37-54.
128. Valentin G., Haas P., Gilmour D. The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Current Biology 2007, 17(12):1026-1031.
129. Vandercappellen J., Van Damme J., Struyf S. The role of CXC chemokines and their receptors in cancer. Cancer Letters 2008, 267(2):226-244.
130. Vauquelin G., Van Liefde I. G protein-coupled receptors: A count of 1001 conformations. Fundamental & Clinical Pharmacology 2005, 19(1):45-56.
131. Verzijl D., Storelli S., Scholten D.J., Bosch L., Reinhart T.A., Streblow D.N., et al. Noncompetitive antagonism and inverse agonism as mechanism of action of nonpeptidergic antagonists at primate and rodent CXCR3 chemokine receptors. Journal of Pharmacology and Experimental Therapeutics 2008, 325(2):544-555.
132. Walser T.C., Rifat S., Ma X., Kundu N., Ward C., Goloubeva O., et al. Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Research 2006, 66(15):7701-7707.
133. Wang Y., Li G., Stanco A., Long J.E., Crawford D., Potter G.B., et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 2011, 69(1):61-76.
134. Wang J., Lu Y., Koch A.E., Zhang J., Taichman R.S. CXCR6 induces prostate cancer progression by the AKT/mammalian target of rapamycin signaling pathway. Cancer Research 2008, 68(24):10367-10376.
135. Wang J.F., Park I.W., Groopman J.E. Stromal cell-derived factor-1alpha stimulates tyrosine phosphorylation of multiple focal adhesion proteins and induces migration of hematopoietic progenitor cells: Roles of phosphoinositide-3 kinase and protein kinase C. Blood 2000, 95(8):2505-2513.
136. Wang J., Shiozawa Y., Wang Y., Jung Y., Pienta K.J., Mehra R., et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. Journal of Biological Chemistry 2008, 283(7):4283-4294.
137. Waugh D.J., Wilson C. The interleukin-8 pathway in cancer. Clinical Cancer Research 2008, 14(21):6735-6741. 10.1158/1078-0432.CCR-07-4843.
138. Wehr A., Baeck C., Heymann F., Niemietz P.M., Hammerich L., Martin C., et al. Chemokine receptor CXCR6-dependent hepatic NK T Cell accumulation promotes inflammation and liver fibrosis. Journal of Immunology 2013, 190(10):5226-5236.
139. Wilson S., Wilkinson G., Milligan G. The CXCR1 and CXCR2 receptors form constitutive homo- and heterodimers selectively and with equal apparent affinities. Journal of Biological Chemistry 2005, 280(31):28663-28674.
140. Wu B., Chien E.Y., Mol C.D., Fenalti G., Liu W., Katritch V., et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010, 330(6007):1066-1071.
141. Wu D., LaRosa G.J., Simon M.I. G protein-coupled signal transduction pathways for interleukin-8. Science 1993, 261(5117):101-103.
142. Wu Y., Wang S., Farooq S.M., Castelvetere M.P., Hou Y., Gao J.L., et al. A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. Journal of Biological Chemistry 2012, 287(8):5744-5755.
143. Youngs S.J., Ali S.A., Taub D.D., Rees R.C. Chemokines induce migrational responses in human breast carcinoma cell lines. International Journal of Cancer 1997, 71(2):257-266.
144. Zhang W., Navenot J.M., Frilot N.M., Fujii N., Peiper S.C. Association of nucleophosmin negatively regulates CXCR4-mediated G protein activation and chemotaxis. Molecular Pharmacology 2007, 72(5):1310-1321.
145. Zhang W.B., Navenot J.M., Haribabu B., Tamamura H., Hiramatu K., Omagari A., et al. A point mutation that confers constitutive activity to CXCR4 reveals that T140 is an inverse agonist and that AMD3100 and ALX40-4C are weak partial agonists. Journal of Biological Chemistry 2002, 277(27):24515-24521.
146. Zhao M., Wimmer A., Trieu K., Discipio R.G., Schraufstatter I.U. Arrestin regulates MAPK activation and prevents NADPH oxidase-dependent death of cells expressing CXCR2. Journal of Biological Chemistry 2004, 279(47):49259-49267.
147. Zlotnik A. Chemokines and cancer. International Journal of Cancer 2006, 119(9):2026-2029.
148. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 1998, 393(6685):595-599.